Aurobindo Pharma share price has gained 4% in one month, but the stock has dropped nearly 10% on a year-to-date (YTD) basis.

Aurobindo Pharma reported a fire at its Penicillin-G facility in Kakinada SEZ, damaging ancillary equipment but sparing core ...

India supplies over 45% of the generics and 15% of biosimilars used in the U.S., with major companies like Dr. Reddy’s, Aurobindo Pharma, Zydus Lifesciences, Sun Pharma, and Gland Pharma earning ...

Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the ...

Generic drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg. The approved ...

An inhalers and derma products manufacturing plant of Aurobindo Pharma subsidiary Aurolife Pharma LLC in the U.S. has been issued 11 observations by the United States Food and Drug Administration.

Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics has received successful trial results for its new bone treatment medicine. The drug, called BP16, is a biosimilar of an existing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pharma stocks such as Sun Pharma, Aurobindo Pharma, Dr Reddy's Lab, Cipla, Gland Pharma, Zydus Lifesciences and Lupin would be in action on Friday after the US President Donald Trump halted ...

Still, he said that they were expecting Trump’s policy to impact the global supply chain, especially for U.S.-based pharma companies that have shifted their production to other regions.

As mentioned, the likes of Teva, Sun Pharma, Dr Reddy's, Cipla, Gland Pharma, Aurobindo Pharmaceuticals, Lupin, Biocon, and Glenmark Pharmaceuticals would surely see their business hit hard by ...

Biocon, Glenmark Pharma and Aurobindo Pharma were the top losers by percentage on the pharma index in Mumbai, down between 2% and 4%. India's pharma exports to the U.S. mostly comprise generics ...